D&D Pharmatech
Biotechnology company developing peptide-based therapeutics (notably GLP-1 class) and related platforms including oral peptide delivery and long-acting formulations. Operates R&D in Korea, a US clinical development affiliate, and affiliated units for large-scale single-cell genomics and radiopharmaceutical development. Pipeline includes oral and injectable peptide candidates, radiotracers, antimicrobial peptides, and programs targeting metabolic, neurodegenerative, fibrotic and oncologic indications.
Industries
Nr. of Employees
small (1-50)
D&D Pharmatech
(13453) Gyeonggi-do, Seongnam-si, Sujeong-gu, Geumto-ro 80beon-gil 27, 4th floor
Patents
Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
US-10406230-B2
View Details
Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
US-10406230-B2
View DetailsProducts
DD01
Once-weekly injectable dual GLP-1/glucagon receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH); US Phase 2 ongoing.
MET-002o
Oral GLP-1 receptor agonist developed with an oral peptide delivery platform; North America Phase 1 initiated.
MET-224o / MET-097o
Oral long-acting GLP-1 candidates combining oral delivery and half-life extension technologies; in IND preparation.
NLY01 (Pegsebrenatide)
Long-acting GLP-1 receptor agonist evaluated for neurodegenerative indications; completed large Phase 2 in North America.
TLY012
Recombinant DR5 agonist intended to induce apoptosis of activated myofibroblasts for fibrotic diseases; received IND acceptance for US Phase 1.
P4M01
Antimicrobial peptide formulated for oral/gum application to treat periodontal disease; completed US Phase 2a with safety and efficacy signals.
DD01
Once-weekly injectable dual GLP-1/glucagon receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH); US Phase 2 ongoing.
MET-002o
Oral GLP-1 receptor agonist developed with an oral peptide delivery platform; North America Phase 1 initiated.
MET-224o / MET-097o
Oral long-acting GLP-1 candidates combining oral delivery and half-life extension technologies; in IND preparation.
NLY01 (Pegsebrenatide)
Long-acting GLP-1 receptor agonist evaluated for neurodegenerative indications; completed large Phase 2 in North America.
TLY012
Recombinant DR5 agonist intended to induce apoptosis of activated myofibroblasts for fibrotic diseases; received IND acceptance for US Phase 1.
P4M01
Antimicrobial peptide formulated for oral/gum application to treat periodontal disease; completed US Phase 2a with safety and efficacy signals.
Services
Design and execution of global clinical trials, CRO oversight and regulatory support for IND and clinical-stage programs.
Generation and analysis of extensive single-cell and single-nucleus datasets from brain tissue using a high-efficiency sequencing platform compatible with frozen samples, combined with GPU-based analytics and machine learning for target nomination.
Design and execution of global clinical trials, CRO oversight and regulatory support for IND and clinical-stage programs.
Generation and analysis of extensive single-cell and single-nucleus datasets from brain tissue using a high-efficiency sequencing platform compatible with frozen samples, combined with GPU-based analytics and machine learning for target nomination.
Expertise Areas
- Peptide drug discovery and optimization
- Oral peptide delivery and formulation development
- Long-acting biologic formulation
- Clinical trial design and global execution
Key Technologies
- Oral peptide delivery techniques (ligandization, lipidation, permeation enhancers)
- Long-acting formulation and half-life extension methods
- High-efficiency single-cell / single-nucleus sequencing for frozen tissues
- GPU-accelerated data analytics and machine learning for genomics
News & Updates
Posters reporting reductions in hepatic steatosis and improved metabolic endpoints after short-term treatment with DD01 were presented at ADA2023 and EASL2023.
Programs and related science are linked to peer-reviewed publications in journals including Nature Communications, Hepatology, Lancet Neurology and Cell Reports describing mechanism and preclinical/clinical data.
Press announcements and filings include patent grants related to oral peptide technology and clinical progress updates.
Company listed on the KOSDAQ market in 2024.
Several licensing and collaboration agreements for development and commercialization of programs, including imaging tracer and peptide program deals reported in corporate timeline.
Posters reporting reductions in hepatic steatosis and improved metabolic endpoints after short-term treatment with DD01 were presented at ADA2023 and EASL2023.
Programs and related science are linked to peer-reviewed publications in journals including Nature Communications, Hepatology, Lancet Neurology and Cell Reports describing mechanism and preclinical/clinical data.
Press announcements and filings include patent grants related to oral peptide technology and clinical progress updates.
Company listed on the KOSDAQ market in 2024.
Several licensing and collaboration agreements for development and commercialization of programs, including imaging tracer and peptide program deals reported in corporate timeline.